Aktueller Stellenwert und Perspektiven der Positronen-Emissions-Tomografie/Computertomografie (PET/CT) in der Diagnostik und Therapie des Lungenkarzinoms

Zusammenfassung

Dieser Übersichtsartikel stellt detailliert die derzeitigen Einsatzgebiete der Positronen-Emissions-Tomografie/Computertomografie (PET/CT) bei dem Management von Lungenkarzinom-Patient*innen dar. Hierbei werden Indikationen, Wertigkeit bei Dignitätsbeurteilung und Stadiierung sowie Nutzen, Limitationen und prognostische Relevanz dieses diagnostischen Hybridverfahrens beleuchtet.

Darüber hinaus bietet diese Publikation einen Ausblick auf neue Radiotracer und mehrschichtige maschinelle Lernverfahren als konsequente Weiterentwicklungen der PET/CT, welche deren diagnostischen, prädiktiven und prognostischen Zusatznutzen zukünftig noch vergrößern wird.

Abstract

This review article presents the current areas of application of positron emission tomography/computed tomography (PET/CT) in the management of lung cancer patients. Indications, the value in the assessment of tumour detection and staging as well as benefits, limitations and prognostic relevance of this diagnostic hybrid method are presented.

In addition, this publication offers an outlook on new radiotracers and multi-layered machine learning processes as coming developments of PET/CT, which will increase its diagnostic, predictive and prognostic impact in the future.

Schlüsselwörter

Positronen-Emissions-Tomografie/Computertomografie - PET/CT - Lungenkarzinom - Bildgebung - Diagnostik - Therapie

Keywords

Positron emission tomography/computed tomography - PET/CT - lung cancer - imaging - diagnosis - therapy

• Literatur

• 1 Krebs in Deutschland für 2015/2016. 12. Ausgabe. Berlin: Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V; 2019
• 2 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms, Langversion 1.0, 2018, AWMF-Registernummer: 020/007OL. Available from (cited 05.02.2021): http://leitlinienprogramm-onkologie.de/Lungenkarzinom.98.0.html
• 3 Boellaard R, Delgado-Bolton R, Oyen WJ. et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 2015; 42: 328-354
• 4 National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer Version 2.2021. Available from (cited 05.02.2021): https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf
• 5 National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer Version 2.2021. Available from (cited 05.02.2021): https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf
• 6 Deutsche Gesellschaft für Nuklearmedizin. DGN-Handlungsempfehlung (S1-Leitlinie): Somatostatinrezeptor-PET/CT. Stand: 3/2017 - AWMF-Registriernummer: 031-046. Available from (cited 05.02.2021) : https://www.nuklearmedizin.de/leistungen/leitlinien/docs/031-046_2017.pdf
• 7 National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors Version 2.2020. Available from (cited 05.02.2021): https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf
• 8 Evangelista L, Ravelli I, Bignotto A. et al. Ga-68 DOTA-peptides and F-18 FDG PET/CT in patients with neuroendocrine tumor: A review. Clin Imaging 2020; 67: 113-116
• 9 Gemeinsamer Bundesausschuss. Richtlinie des Gemeinsamen Bundesausschusses zu Untersuchungs- und Behandlungsmethoden der vertragsärztlichen Versorgung, zuletzt geändert am 15. Oktober 2020, veröffentlicht im Bundesanzeiger (BAnz AT 19.01.2021 B1), in Kraft getreten am 20. Januar 2021. Available from (cited 05.02.2021): https://www.g-ba.de/richtlinien/7/
• 10 Kassenärztliche Bundesvereinigung. Vereinbarung von Qualitätssicherungsmaßnahmen nach § 135 Abs. 2 SGB V zur diagnostischen Positronenemissionstomographie, diagnostischen Positronenemissionstomographie mit Computertomographie (QS-Vereinbarung PET, PET/CT), vom 01.07.2016, in der ab dem 01.04.2020 geltenden Fassung. Available from (cited 05.02.2021): https://www.kbv.de/media/sp/PET_CT.pdf
• 11 Madsen PH, Holdgaard PC, Christensen JB. et al. Clinical utility of F-18 FDG PET-CT in the initial evaluation of lung cancer. Eur J Nucl Med Mol Imaging 2016; 43: 2084-2097
• 12 Rami-Porta R, Bolejack V, Crowley J. et al. The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2015; 10: 990-1003
• 13 Schmidt-Hansen M, Baldwin DR, Hasler E. et al. PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer. Cochrane Database Syst Rev 2014; 11: Cd009519
• 14 Shroff GS, Viswanathan C, Carter BW. et al. Staging Lung Cancer: Metastasis. Radiol Clin North Am 2018; 56: 411-418
• 15 van Tinteren H, Hoekstra OS, Smit EF. et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002; 359: 1388-1393
• 16 Zeliadt SB, Loggers ET, Slatore CG. et al. Preoperative PET and the reduction of unnecessary surgery among newly diagnosed lung cancer patients in a community setting. J Nucl Med 2014; 55: 379-385
• 17 Kaseda K. Recent and Current Advances in FDG-PET Imaging within the Field of Clinical Oncology in NSCLC: A Review of the Literature. Diagnostics (Basel) 2020; 10: 561
• 18 Wang J, Welch K, Wang L. et al. Negative predictive value of positron emission tomography and computed tomography for stage T1-2N0 non-small-cell lung cancer: a meta-analysis. Clin Lung Cancer 2012; 13: 81-89
• 19 Tönnies S, Tönnies M, Kollmeier J. et al. Impact of preoperative 18F-FDG PET/CT on survival of resected mono-metastatic non-small cell lung cancer. Lung Cancer 2016; 93: 28-34
• 20 Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 1985; 312: 1604-1608
• 21 Tönnies S, Bauer TT, Misch D. et al. [Staging with 18F-FDG-PET/CT influences stage-specific survival in advanced non-small cell lung cancer (NSCLC)]. Pneumologie 2012; 66: 212-217
• 22 Theodoropoulos AS, Gkiozos I, Kontopyrgias G. et al. Modern radiopharmaceuticals for lung cancer imaging with positron emission tomography/computed tomography scan: A systematic review. SAGE Open Med 2020; 8
• 23 Wong CW, Chaudhry A. Radiogenomics of lung cancer. J Thorac Dis 2020; 12: 5104-5109
• 24 Teramoto A, Yamada A, Tsukamoto T. et al. Decision Support System for Lung Cancer Using PET/CT and Microscopic Images. Adv Exp Med Biol 2020; 1213: 73-94
• 25 Ninatti G, Kirienko M, Neri E. et al. Imaging-Based Prediction of Molecular Therapy Targets in NSCLC by Radiogenomics and AI Approaches: A Systematic Review. Diagnostics (Basel) 2020; 10: 359
• 26 Unterrainer M, Ruzicka M, Fabritius MP. et al. PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions. Eur Radiol Exp 2020; 4: 63
• 27 Lang D, Wahl G, Poier N. et al. Impact of PET/CT for Assessing Response to Immunotherapy-A Clinical Perspective. J Clin Med 2020; 9: 3483
• 28 Alongi P, Laudicella R, Desideri I. et al. Positron emission tomography with computed tomography imaging (PET/CT) for the radiotherapy planning definition of the biological target volume: PART 1. Crit Rev Oncol Hematol 2019; 140: 74-79
• 29 Dahlsgaard-Wallenius SE, Hildebrandt MG, Johansen A. et al. Hybrid PET/MRI in non-small cell lung cancer (NSCLC) and lung nodules-a literature review. Eur J Nucl Med Mol Imaging 2021; 48: 584-591
• 30 Li J, Zhou H, Zhang X. et al. A two-way comparison of whole-body 18FDG PET-CT and whole-body contrast-enhanced MRI for distant metastasis staging in patients with malignant tumors: a meta-analysis of 13 prospective studies. Ann Palliat Med 2020; 9: 247-255